A critical review of early-onset and late-onset preeclampsia

Obstetrical and Gynecological Survey

Volumn 66, Issue 8, 2011, Pages 497-506

  Raymond, Dahlia ^a   Peterson, Erika ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PENTRAXIN 3; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; EARLY ONSET PREECLAMPSIA; FEMALE; HUMAN; IMMUNE SYSTEM; LATE ONSET PREECLAMPSIA; LIPID PEROXIDATION; NATURAL KILLER CELL; OXIDATIVE STRESS; PATHOGENESIS; PREECLAMPSIA; PREGNANCY; REPRODUCTION; REVIEW;

BIOLOGICAL MARKERS; FEMALE; HUMANS; OXIDATIVE STRESS; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTERS;

EID: 80155140296     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3182331028     Document Type: Review

References (98)

1. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of preeclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009;338:1-5.
2. Deleted in proof.
3. Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007;109: 1368-1374. (Pubitemid 46869876)
4. Deleted in proof.
5. Deleted in proof.
6. Deleted in proof.
7. Deleted in proof.
8. Stepan H, Unversucht A, Wessel N, et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49:818-824. (Pubitemid 351664216)
9. Obed SA, Aniteye P. Birth weight and ponderal index in preeclampsia: a comparative study. Ghana Medical J. 2006;40: 8-13.
10. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22:143-148. (Pubitemid 37521365)
11. Deleted in proof.
12. Ihle BU, Long P, Oats J. Early onset preeclampsia: recognition of underlying renal disease. Br Med J. 1987;294:79-81. (Pubitemid 17230086)
13. Onah HE, Iloabachie GC. Conserative management of earlyonset preeclampsia and fetomaternal outcome in Nigeria. J Obstet Gynaecol. 2002;22:357-362.
14. Crispi F, Llurba E, Dominguez C, et al. Predictive value of angiogenic factors and uterine artery Doppler for early-versus late-onset preeclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol. 2008;31:303-309.
15. Dissanayake VH, Samarasinghe HD, Morgan L, Jayasekara RW, Seneviratne HR, Broughton Pipkin F. Morbidity and mortality associated with preeclampsia at two tertiary care hospitals in Sri Lanka. J Obstet Gynaecol Res. 2007;33:56-62. (Pubitemid 46025394)
16. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med. 2008;18: 186-194.
17. Gauster M, Moser G, Orendi K, et al. Factors involved in regulating trophoblast fusion: potential role in the development of preeclampsia. Placenta. 2009;30:S49-S54.
18. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69: 1-7. (Pubitemid 36806800)
19. Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost. 2009;7:375-384.
20. Redman CW, Sargent IL. Placental stress and preeclampsia: a revised view. Placenta. 2009;30(suppl A):S38-S42.
21. Burton GJ, Woods AW, Jauniaux E, et al. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during pregnancy. Placenta. 2009;30:473-482.
22. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51:970-975. (Pubitemid 351398986)
23. Guller S. Role of the syncytium in placenta-mediated complications of preeclampsia. Thromb Res. 2009;124:389-392.
24. Kim YK, Lee DS, Jeong DH, et al. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn. 2009;29:464-470.
25. Grill S, Rusterholz C, Zanetti-Dallenbach R, et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol. 2009;7:1-14.
26. Oudejans CB, van Dijk M, Oosterkamp M, et al. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120:607-612. (Pubitemid 44942844)
27. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009;24:147-158.
28. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40-49. (Pubitemid 43927490)
29. Steinberg G, Khankin EV, Karumanchi SA. Angiogenic factors and preeclampsia. Thromb Res. 2009;123:S93-S99.
30. Hirashima C, Ohkuchi A, Matsubara S, et al. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res. 2008;31:1541-1548.
31. Crispi F, Dominguez C, Llubra E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol. 2006; 195:201-207. (Pubitemid 43927524)
32. Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151-159. (Pubitemid 46541789)
33. Wikstrom AK, Larrson A, Eriksson UJ, et al. Early postpartum changes in circulating pro-and anti-angiogenic factors in early-onset and late-onset preeclampsia. Acta Obstetet Gynecol. 2008;87:146-153. (Pubitemid 351171539)
34. Savvidou M, Akolekar R, Zaragoa E, et al. First trimester urinary placental growth factor and development of preeclampsia. BJOG. 2009;116:643-647.
35. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth and stillbirth. Obstet Gynecol. 2007;109:1316-1324. (Pubitemid 46869870)
36. Masuyama H, Suwaki N, Nakatsukasa H, et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006;194:551-556. (Pubitemid 43183715)
37. Lykke JA, Langhoff-Roos J, Sibai BM. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944-951.
38. Levine RJ, Qian C, Maynard CE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006; 194:1034-1041.
39. Baumann MU, Bersinger NA, Mohaupt MG, et al. Firsttrimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 2008;199:1-6.
40. Herse F, Verlohren S, Wenzel K, et al. Prevalence of agonostic autoantibodies II against the angiotensin II type 1 receptor and soluble fms-like tytosine kinase 1 in a gestational agematched case study. Hypertension. 2009;53:393-398.
41. De Vivo A, Baviera G, Giordano D, et al. Endoglin, PlGF and sFlt-1 as markers for predicting preeclampsia. Acta Obstet Gynecol Scand. 2008;87:837-842.
42. Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197:244.e1-244.e8.
43. Nadar SK, Karalis I, Al Yemeni E, et al. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost. 2005;94:1071-1076. (Pubitemid 41645951)
44. Gotsch F, Romero R, Kusanovic JP, et al. Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med. 2008;21:389-402. (Pubitemid 351999171)
45. Tripathi R, Rath G, Jain A, et al. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by preeclampsia. Ann Anat. 2008;190:477-489.
46. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol. 2004;190:1541-1550. (Pubitemid 39006187)
47. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-ecclampsia. J Matern Fetal Neonatal Med. 2005;17:3-18. (Pubitemid 40515938)
48. Wathen KA, Ylikorkala O, Andersson S, et al. Maternal serum endostatin at gestational weeks 16-20 is elevated in subsequent preeclampsia but not in intrauterine growth retardation. Acta Obstet Gynecol Scand. 2009;88:593-598.
49. Mahmound RA, Abdel-Raouf M. Serum endostatin and vascular endothelial growth factor levels in patients with preeclampsia. East Mediterr Health J. 2006;12:178-187.
50. Hirtenlehner K, Pollheimer J, Lictenberger C, et al. Elevated serum concentrations of the angiogenesis inhibitor endostatin in preeclamptic women. J Soc Gynecol Investig. 2003;10: 412-417. (Pubitemid 37159227)
51. Wikstrom AK, Larsson A, Akerud H, et al. Increased circulating levels of the antiangiogenic factor endostatin in early-onset but not late-onset preeclampsia. Reprod Sci. 2009;16:995-1000.
52. Anteby EY, Greenfield C, Natanson-Yaron S, et al. Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and-10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol Hum Reprod. 2004;10:229-235. (Pubitemid 38456027)
53. Leach RE, Romero R, Kim Y, et al. Preeclampsia and expression of heparin-binding EGF-like growth factor. Lancet. 2002; 360:1215-1219. (Pubitemid 35232721)
54. Percaoli MT, Menegon FT, Borges VT, et al. Platelet aggregation and TGF-beta(1) plasma levels in pregnant women with preeclampsia. J Reprod Immunol. 2008;79:79-84.
55. Moll SJ, Jones CJ, Crocker IP, et al. Epidermal growth factor rescues trophoblast apoptosis induced by reactive oxygen species. Apoptosis. 2007;12:1611-1612.
56. Imudia AN, Kilburn BA, Petkova A, et al. Expression of heparin-binding EGF-like growth factor in term chorionic villous explants and its role in trophoblast survival. Placenta. 2008;29:784-789.
57. Huber A, Hefler L, Tempfer C, et al. Transforming growth factor-beta 1 serum levels in pregnancy and preeclampsia. Acta Obstet Gynecol Scand. 2002;81:168-171. (Pubitemid 34242375)
58. Hennessy A, Orange S, Willis N, et al. Transforming growth factor-beta 1 does not relate to hypertension in preeclampsia. Clin Exp Pharmacol Physiol. 2002;29:968-971. (Pubitemid 35177163)
59. Purwosunu Y, Sekizawa A, Yoshimura S, et al. Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. Reprod Sci. 2009;16:857-864.
60. Stanczuk GA, Mccoy MJ, Hutchinson IV, et al. The genetic predisposition to produce high levels of TGF-beta1 impacts on the severity of eclampsia/preeclampsia. Acta Obstet Gynecol Scand. 2007;86:903-908. (Pubitemid 47123591)
61. Kopcow HD, Karumanchi SA. Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. J Reprod Immunol. 2007;76:23-29. (Pubitemid 350100881)
62. Lindheimer MD, Umans JG. Explaining and predicting preeclampsia. N Engl J Med. 2006;355:1056-1058. (Pubitemid 44343551)
63. Zhu YC, Sun Y, Yang HX, et al. Profile of serum endoglin in pregnant women with severe preeclampsia and eclampsia [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2009;44:91-93.
64. Stephan H, Jank A. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198:175.e1-175.e6.
65. Khalil A, Jauniaux E, Harrington K. Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. Obstet Gynecol. 2009;113:646-654.
66. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for preeclampsia: a prospective longitudinal study. BJOG. 2008;115:1465-1472.
67. Spencer K, Cowans NJ, Chefetz I, et al. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of preeclampsia. Prenat Diagn. 2007;27: 258-263. (Pubitemid 46450585)
68. Goswami D, Tannetta DA, Magee LA, et al. Excess syncytiotrophoblast microparticle shedding is a feature of earlyonset preeclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006;27:56-61. (Pubitemid 41662880)
69. Moffett A, Hiby SE. How does the maternal immune system contribute to the development of preeclampsia. Placenta. 2007;28(suppl A):S51-S56. (Pubitemid 46506049)
70. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet. 2005;365:785-799.
71. Riley JK, Yokoyama WM. NK cell tolerance and the maternalfetal interface. Am J Reprod Immunol. 2008;59:371-387.
72. Reister F, Kingdom JC, Ruck P, et al. Altered protease expression by periarterial trophoblast cells in severe early-onset preeclampsia with IUGR. J Perinat Med. 2006;34:272-279. (Pubitemid 44114562)
73. Schiessl B. Inflammatory response in preeclampsia. Mol Aspects Med. 2007;28:210-219. (Pubitemid 46843193)
74. Sargent IL, Borzychowski AM, Redman CW. NK cells and preeclampsia. J Reprod Immunol. 2007;76:40-44.
75. Cackovic M, Buhimschi CS, Zhao G, et al. Fractional excretion of tumor necrosis factor-alpha in women with severe preeclampsia. Obstet Gynecol. 2008;112:93-100.
76. Seki H, Matuoka K, Inooku H, et al. TNF-alpha from monocyte of patients with preeclampsia-induced apoptosis in human trophoblast cell line. J Obstet Gynaecol Res. 2007;33:408-416. (Pubitemid 47222721)
77. Hung TH, Charnock-Jones DS, Skepper JN, et al. Secretion of tumor necrosis factor-from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol. 2004;164:1049-1061. (Pubitemid 38235486)
78. Luppi P, DeLoia JA. Monocytes of preeclamptic women spontaneously synthesize pro-inflammatory cytokines. Clin Immunol. 2006;118:268-275. (Pubitemid 43199666)
79. Odegard RA, Vatten LJ, Nilsen ST, et al. Umbilical cord plasma interleukin-6 and fetal growth restriction in preeclampsia: a prospective study in Norway. Obtset Gynecol. 2001;98: 289-294. (Pubitemid 32744764)
80. Iademarco MF, McQuillan JJ, Dean DC. Vascular cell adhesion molecule 1: contrasting transcriptional control mechanisms in muscle and endothelium. Proc Natl Acad Sci. 2003; 90:3943-3947.
81. Krauss T, Azab H, Dietrich M, et al. Fetal plasma levels of circulating endothelial cell adhesion molecules in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. 1998;78:41-45. (Pubitemid 28186862)
82. Donker RB, Molema G, Faas MM, et al. Absence of in vitro generalized pro-inflammatory endothelial activation in severe, early-onset preeclampsia. J Soc Gynecol Investig. 2005;12: 518-528. (Pubitemid 41395241)
83. Oyama R. The relationship between the level of expression of intracellular adhesion molecule-1 in placenta and onset of preeclampsia. J Obstet Gynaecol. 2001;27:147-164.
84. Mazouni C, Capo C, Ledu R, et al. Preeclampsia: impaired inflammatory response mediated by Toll-like receptors. J Reprod Immunol. 2008;78:80-83. (Pubitemid 351609121)
85. Molvarec A, Jermendy A, Kovacs M, et al. Toll-like receptor 4 gene polymorphisms and preeclampsia: lack of association in a Caucasian population. Hypertens Res. 2008;31:859-864. (Pubitemid 351895029)
86. van Rijn BB, Frank A, Steegers EA, et al. Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome. PLoS One. 2008;3:e1865.
87. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiopnectin. Endocrinology. 2007;148:5478-5486. (Pubitemid 350012628)
88. Shah DM. Activation of NF-kappaB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. Am J Obstet Gynecol. 2007;196:48.e1-48.e8.
89. Rovere-Querini P, Antonacci S, Dell'Antonio G, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148-155. (Pubitemid 44336858)
90. Aban M, Cinel L, Arslan M, et al. Expression of nuclear factorkappa B and placental apoptosis in pregnancies complicated with intrauterine growth restriction and preeclampsia: an immunhistochemical study. Tohoku J Exp Med. 2004;204:195-202. (Pubitemid 39619137)
91. Akolekar R, Casagrandi D, Livanos P, et al. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:934-938.
92. Cetin I, Cozzi V, Papageorghiou AT, et al. First trimester PTX3 levels in womwn who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand. 2009;88:846-849.
93. Poston L, Raijmakers TM. Trophoblast oxidative stress, antioxidants and pregnancy outcome-a review. Placenta. 2004; 18:S72-S78. (Pubitemid 38514960)
94. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004;11: 342-352. (Pubitemid 39185874)
95. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222:222-235.
96. Raijmakers MT, Peters WH, Steegers EA, et al. NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. Placenta. 2004;25:S85-S89. (Pubitemid 38514962)
97. Gupta S, Agarwal A, Sharma RK. The role of placental oxidative stress and lipid peroxidation in preeclampsia. Obstet Gynecol Surv. 2005;60:807-816. (Pubitemid 41698019)
98. Basbug M, Demir I, Serin IS, et al. Maternal erythrocyte malonialdehyde level in preeclampsia prediction: a longitudinal study. J Perinat Med. 2003;31:469-474. (Pubitemid 38057002)